In light of the COVID-19 outbreak, recruitment to Baby-OSCAR was paused on 18th March 2020. Recruitment has now re-started in a small number of sites. If you have any queries please contact the Trial Team directly.


This research is about babies who have been born early (prematurely).

The aim of this study is to find out whether or not a confirmed large Patent Ductus Arteriosus (PDA) in very premature babies should be treated with ibuprofen within 72 hours of birth.

The study title is: Outcome after Selective Early Treatment for Closure of Patent Ductus ARteriosus in Pre-term Babies, or Baby-OSCAR in short.


The latest baby was recruited at Queen Charlotte's & Chelsea Hospital on 20 May 2020

Co-ordination, Sponsorship and Funding

This multi-centre trial is co-ordinated from the National Perinatal Epidemiology Unit Clinical Trial unit (NPEU CTU) at the University of Oxford and is sponsored by the University of Oxford. Funding is provided by the National Institute of Health Research (NIHR) Health Technology Assessment (HTA) programme (project reference 11/92/15).  The ISRCTN is: 84264977.

If you are a doctor, or other health professional, for further information please refer to the 'Protocol' and 'Information for Hospitals' sections.  For the latest news please click on our Newsletter.

If you are a parent, please refer to the 'Information for Parents' section of this website.

Trial Information

EudraCT No.:
REC Reference:
Clinical Trials Unit:
National Perinatal Epidemiology Unit CTU
University of Oxford
NIHR Health Technology Assessment (HTA) Programme
Recruitment Target:
Duration of Study:
April 2014 - February 2021

Disclaimer: The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NHS, NIHR or the Department of Health.

Updated: Thursday, 04 June 2020 16:16 (v104)